Methizol

Quick links to important sections

Methizol

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Methizol

Property Description
Active ingredient Thiamazole (also known as Methimazole)
Form Oral Solid Preparation (Tablet)
Pharmacological class Antithyroid Agent (Thyreostatic Drug)
General purpose To moderate an overactive metabolism
Origin Synthetic drug (Thiocarbamide derivative)

What Type of Medicine is Methizol (Thiamazole)?

Methizol is a synthetic drug that belongs to the therapeutic class of Antithyroid Agents, or thyreostatic drugs, which are designed to modulate the function of the thyroid gland. Its single active ingredient is Thiamazole, a substance also widely known by the non-proprietary name Methimazole. Chemically, Thiamazole is identified as a thiourea derivative. This medicine is consistently presented as an oral solid preparation—specifically, a tablet—intended for oral administration. As a prescription-only medicine, Methizol is clinically recognized for its efficacy in managing excessive thyroid hormone activity. Its presentation as a standardized tablet formulation ensures predictable oral bioavailability, a critical factor for long-term therapeutic control.


How Does Methizol Act and What is its General Purpose?

The physiological action of Methizol's active ingredient, Thiamazole, is to function as a potent thyroid peroxidase inhibitor, which slows the body's overactive hormone production. Its general purpose is to effectively moderate an overactive metabolism by reducing the amount of thyroid hormones (T3 and T4) circulating in the bloodstream. The drug achieves this effect by interfering with the enzyme responsible for incorporating iodine—a necessary raw material—into the hormone structure, thereby limiting the synthesis of thyroid hormones.

Antithyroid medications like Thiamazole are a key strategy for achieving biochemical normalization of thyroid function. This means the medicine works to return the body’s metabolic rate toward a stable, healthy baseline. Thiamazole is recognized as a primary treatment option within the class of thyreostatic drugs. By acting on this fundamental production process, this thyreostatic drug helps to guide the thyroid system back toward a necessary balance.

Regulatory References

  1. Methimazole: MedlinePlus Drug Information
  2. Antithyroid drug regimen for treating Graves' hyperthyroidism | Cochrane

What side effects are possible with Methizol?

Possible Side Effects and Safety Information

The safety profile for Methizol is characterized by a spectrum of adverse reactions, ranging from common, generally mild events to rare, potentially life-threatening systemic disorders, as officially documented in government regulatory sources.

Key Adverse Reaction Categories

Classification Examples of Documented Reactions
Rare, Life-Threatening Events Agranulocytosis (a severe drop in white blood cell count), Aplastic Anemia, Acute Liver Failure/Severe Hepatotoxicity, and ANCA-positive Vasculitis.
Common Minor Events Rash, itching, nausea, vomiting, joint pain (arthralgia), headache, and loss of taste.
Systemic & Immunologic Lupus-like syndrome, Drug fever, and other generalized immune reactions affecting the skin or joints.

Serious Safety Restrictions and Considerations

  • Blood System Risk: Agranulocytosis typically occurs within the first few months of starting therapy, but it can manifest later. The drug must be immediately discontinued if there is confirmed evidence of agranulocytosis or other serious blood disorders.
  • Liver Toxicity: Although the risk is generally considered low, Methizol has been associated with hepatotoxicity, which can progress to acute liver failure. Monitoring of liver function tests is required, and the drug must be stopped if clinically significant evidence of liver abnormality occurs.
  • Pregnancy: Methizol readily crosses the placenta and is associated with specific congenital defects (e.g., aplasia cutis, choanal atresia) primarily when used during the first trimester of pregnancy. It can also cause fetal goiter and cretinism, underscoring the need for careful dosing to control the mother’s thyroid disease with the lowest possible dose. A history of drug-induced acute pancreatitis is a formal contraindication to its use.
  • Hypothyroidism: The therapy can lead to drug-induced hypothyroidism, which is managed through routine monitoring of thyroid hormone levels and dosage adjustment.

Overdose and Emergency Response

If a potential overdose of Methizol (Methimazole) is suspected, it is critical to seek emergency medical attention or call the Poison Help line immediately. Overdose can present with a range of symptoms, from less severe signs to serious, potentially delayed, or life-threatening effects.

Symptoms and Presentations of Overdose

Initial and less frequent symptoms documented in official labeling include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus (itching), and edema (swelling). Overdose may also affect the nervous system, potentially causing stimulation or depression, and less commonly, may lead to hepatitis, nephrotic syndrome, and exfoliative dermatitis.

Serious and Delayed Manifestations

A critical concern following overdose is the potential for severe hematologic effects, specifically aplastic anemia (pancytopenia) or agranulocytosis. These conditions may not be immediately apparent, as they can be manifested hours to days after the exposure.

Emergency Action

The required action in the event of an overdose is to seek urgent medical care. Treatment involves appropriate supportive management tailored to the patient's medical status, and healthcare providers are advised to consider the possibility of multiple drug overdoses, drug interactions, and unusual drug kinetics during care. A certified Regional Poison Control Center is a resource for current treatment information. No specific toxic dose is officially established in the regulatory documents.

Therapeutic Uses of Methizol

What Methizol Treats: Main Uses and Benefits

Methizol (Thiamazole) is commonly used to help with symptoms related to physical discomfort in conditions where symptoms may intensify temporarily, most notably Graves' disease and toxic multinodular goiter. Its use plays a role in managing conditions associated with heightened physiological stress, supporting general well-being during symptomatic phases.


The medication is considered relevant for easing symptom clusters that may become intense or disruptive, especially those symptoms related to systemic imbalance. It helps address signs such as a rapid heart rate (tachycardia), uncomfortable palpitations, intense anxiety, tremor, and significant heat intolerance. The primary benefit is that Methizol contributes to easing distress and assists with maintaining functional stability related to symptoms that interfere with daily functioning.

Methizol is commonly used across conditions presenting with acute episodes, such as situations involving pronounced thyrotoxic manifestations. It may also be part of symptomatic management in scenarios where additional management of discomfort is required before procedures like thyroidectomy or radioactive iodine therapy. This use in pre-procedure contexts contributes to easing the overall symptom load during these critical phases, supporting patients during difficult episodes by easing distress.


Quick Fact: Supportive Management for Cardioneurological Symptoms

The use of Methizol is relevant for easing the impact of symptoms that create noticeable physiological strain, assisting with managing symptoms related to increased neurological or muscular activity.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Methizol (Thiamazole) eligibility is determined by specific regulatory criteria concerning patient health status and age. The medicine is primarily allowed for use in adults and children diagnosed with hyperthyroidism due to Graves' disease or toxic multinodular goiter, often utilized before procedures like thyroidectomy.

Use is strictly contraindicated in populations with known hypersensitivity to Thiamazole or any component of the formulation. Absolute non-eligibility also applies to patients with pre-existing hematologic disorders, such as agranulocytosis or aplastic anemia, and those with significant pre-existing hepatic disease, including hepatitis or jaundice.

Specific restrictions apply to certain groups. The medicine is not recommended for children under 2 years old due to insufficient safety data. Use during pregnancy is highly restricted (Pregnancy Category D), especially in the first trimester, due to risk of congenital defects, and requires the lowest possible effective dose. Patients with renal impairment or hepatic dysfunction must receive careful dose adjustments or discontinue treatment, respectively, based on their condition.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Methizol (also known as methimazole) may interact with certain other medicines, primarily due to the drug's effect on thyroid status and, in some cases, its impact on vitamin K activity. A shift from a hyperactive thyroid state to a normal (euthyroid) state while taking Methizol can alter how the body processes concurrent medications.


Interacting Product Category Potential Effect & Management Note
Oral Anticoagulants (e.g., Warfarin) Methizol may potentially increase the anticoagulant effect due to inhibition of vitamin K activity. Close monitoring of blood clotting tests (PT/INR) and dose adjustment of the anticoagulant may be needed.
beta-Adrenergic Blocking Agents Clearance of beta-blockers may decrease as the patient becomes euthyroid. A dose reduction of the beta-blocker may be required.
Digitalis Glycosides Serum levels of digitalis may increase as the patient becomes euthyroid. A reduced dosage of digitalis glycosides may be necessary.
Xanthine Derivatives (e.g., Theophylline) The clearance of theophylline may decrease as the patient becomes euthyroid. A dose reduction may be necessary.

Particular care should also be taken if Methizol is used alongside other drugs known to cause agranulocytosis.

Mechanism of Action

Methizol is classified as a thionamide compound that selectively accumulates within the thyroid gland.

Its primary biological target is the enzyme thyroid peroxidase (TPO), a heme-containing protein embedded in the apical membrane of thyroid follicular cells. Methizol functions as a non-competitive or competitive inhibitor of TPO activity. This interaction directly prevents the enzyme from catalyzing two essential molecular steps in the intracellular pathway of thyroid hormone synthesis:

  1. The oxidation of iodide ion ( I^-) to its reactive form.
  2. The subsequent organification (incorporation) of this iodine into the tyrosine residues of thyroglobulin.

Furthermore, Methizol interferes with the coupling of two iodinated tyrosine molecules (monoiodotyrosine and diiodotyrosine) to form the circulating hormones, thyroxine ( T4) and triiodothyronine ( T3).

The downstream cascade is a substantial reduction in the synthesis of new T4 and T3. Since Methizol does not affect the release of preformed hormones stored in thyroglobulin, the system-level physiological consequence is a gradual decrease in circulating plasma levels of T4 and T3 as existing reserves are metabolized.

Dosage and Administration Information

How to Use Methizol

Methizol (Thiamazole) is administered orally as a tablet for systemic control, following a structured, two-phase treatment regimen. The dosage strengths available are typically 5 mg and 10 mg tablets.


Dosing and Frequency Patterns

Treatment begins with an initial high-dose phase and transitions to a lower maintenance dose once the euthyroid state is achieved. For adults, the initial dose can range from 15 mg up to 60 mg daily, depending on the severity of the condition. During this initial phase, the total daily dosage is generally taken in three divided doses at regular intervals to establish control. Once normalized, the patient progresses to a maintenance dose, typically between 5 mg and 15 mg daily, which can be taken once daily.


Administration Context and Special Conditions

Tablets should be taken whole with liquid and are generally recommended to be administered after meals. If a dose is missed, it should be skipped if the next scheduled dose is near, avoiding the taking of a double dose. The medication is also utilized to achieve a euthyroid state prior to definitive procedures such as thyroidectomy or radioactive iodine therapy.

Population-Specific Use

For pediatric patients, initial dosing is calculated by body weight (0.4 mg/kg daily). For patients with hepatic or renal impairment, treatment involves careful, individualized dose adjustment, with the dose kept as low as possible.

Recent Clinical Evidence

Research evidence / Overview of studies for Methizol

Evidence for Initial Management of Hyperthyroidism

Research for managing Graves' disease primarily relies on Randomized Controlled Trials (RCTs) and Systematic Reviews that evaluate treatment strategies. These studies monitor biomarker changes, specifically measuring thyroid hormone ( fT4, T3, TSH) levels and the rate at which patients move toward a euthyroid state. Findings describe patterns in the time required for hormone levels to shift toward the normal range. Comparative trials have also been studied, but the established use of this medicine means recent placebo-controlled trials are not available. What is known comes from studies exploring how patients’ symptoms evolve in the observed groups.


Evidence for Toxic Multinodular Goiter and Pre-Procedure Use

Research includes dedicated RCTs on Toxic Multinodular Goiter (TMNG), which monitored the time to achieve and sustain normal thyroid function. Additionally, Methizol was evaluated in short-term pre-procedure contexts before definitive treatments like thyroidectomy or Radioactive Iodine (RAI) therapy. For surgical preparation, research examined the achievement of a euthyroid state. For RAI preparation, studies explored the impact of using the drug beforehand on the risk of persistent hyperthyroidism following the procedure. The use of the drug in short-term, pre-procedure protocols was studied and is referenced in clinical practice guidelines.


⏳ Long-Term Studies and Durability of Response

Numerous long-term observational studies track patients over many years, measuring the remission rate and the recurrence rate of hyperthyroidism after treatment is completed. These research efforts help contextualize group patterns but do not provide individual predictions. Long-term effects are not fully established regarding the single best duration of therapy required to minimize recurrence risk, and evidence quality varies across studies due to differences in design and patient selection.


Evidence in Specific Study Populations

The majority of clinical data is derived from studies on adults. However, Methizol was evaluated in some studies focusing specifically on pediatric patients. Research also includes studies on older adults, where outcomes related to physiological strain were monitored. Research indicates that sample sizes were modest in many trials focusing on these specific groups compared to the main adult studies, meaning data for certain groups remain insufficient.


Key Research Gaps and Uncertainties

Key research gaps include the heterogeneity (variability) found across different studies, making direct comparisons difficult, especially regarding optimal treatment duration. Furthermore, existing studies provide limited information for long-term outcomes regarding reliable biomarkers that could predict which patients are most likely to experience long-term remission. The results apply only to the populations studied, meaning findings describe group patterns and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Antithyroid drugs for Graves' disease: a systematic review and meta-analysis
  2. Toxic Multinodular Goiter: Long-Term Management and Treatment Options
  3. Thiamazole (Methimazole): MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Methizol (FAQ)

Q: How long does it usually take to feel the effects of Methizol?

A: Studies and official information indicate that symptom improvement, such as feeling a calmer heart rate, may be observed within 2 to 4 weeks of initiating therapy. However, achieving a stable, normal thyroid hormone level (a state called euthyroid) often requires 6 to 12 weeks of continuous treatment.

Q: Is Methizol a medication you have to take forever?

A: No, official guidance does not describe Methizol as a medication that must be taken forever. Treatment duration is often in the range of 12 to 18 months, which is followed by an assessment to determine if long-term remission has been achieved. The total length of therapy is determined by a healthcare professional.

Q: What common over-the-counter medicines should not be mixed with Methizol?

A: Methizol may affect the activity of Vitamin K in the body, which is present in some supplements. Additionally, over-the-counter supplements containing high-dose Biotin (Vitamin B7) may need to be paused before thyroid function blood tests, as Biotin can interfere with the accuracy of the results.

Q: Can older adults safely use Methizol?

A: Yes, older adults can use Methizol, but dose modification may be necessary due to the higher likelihood of age-related issues like kidney or liver impairment. Close monitoring for serious adverse effects is generally recommended in this population.

Q: Why does Methizol require a prescription?

A: The medicine is prescription-only because it requires close, ongoing medical supervision. This requirement reflects the need for supervision due to the potential risk of rare but serious adverse reactions, such as agranulocytosis (a severe drop in white blood cells) and liver damage. Regular blood testing is required.

Q: Why is Methizol often taken at a specific time of day?

A: The medication is typically structured to be taken at regular intervals to maintain consistent levels of the drug in the blood. Official guidance generally recommends administering the tablets after meals. This context can help minimize the potential for common gastrointestinal side effects like nausea or stomach upset.

Q: What is the expected duration of treatment with Methizol?

A: For managing Graves’ disease, continuous treatment generally falls into the range of 12 to 18 months after the initial phase has achieved normal hormone levels. The final treatment duration is based on clinical guidelines and individual patient response.

Q: Is Methizol considered a high-risk medication by regulatory bodies?

A: Regulatory documents indicate that Methizol is associated with rare, potentially life-threatening adverse effects, including severe liver failure and agranulocytosis. These risks necessitate prompt medical evaluation if symptoms of concern are observed.

Q: Is there a link between Methizol and weight gain or loss?

A: Weight changes may occur. Loss of appetite and weight loss are documented side effects. However, if the medication causes thyroid hormone levels to drop too low (hypothyroidism), weight gain is also noted as a potential consequence of that condition.

Q: Does Methizol cause drowsiness or fatigue?

A: Drowsiness (sleepiness) is listed in official documents as an uncommon side effect. Additionally, unusual tiredness or weakness (fatigue) may be a symptom of drug-induced hypothyroidism, which may prompt the need for a dose adjustment.

Q: Can taking Methizol affect my sleep?

A: The medication’s safety profile includes central nervous system effects such as dizziness and drowsiness. These potential side effects may interfere with normal alertness or sleep patterns, according to regulatory information.

Q: Does alcohol interact negatively with Methizol?

A: Official information advises caution regarding heavy or daily alcohol consumption while on therapy. Methizol is processed by the liver, and combining it with excessive alcohol intake is associated with an increased risk of severe liver injury (hepatotoxicity).

Q: Are there any specific foods or drinks to avoid while taking Methizol?

A: No specific foods or drinks are formally prohibited. However, supplements containing high-dose Biotin (Vitamin B7) may require temporary cessation before thyroid function blood tests, as Biotin can interfere with the accuracy of the lab results.

Q: What is the safety classification of Methizol for breastfeeding?

A: Methizol is generally considered acceptable for use during breastfeeding at low to moderate doses (up to 20 mg daily). Studies indicate that the amount of medication transferred to the infant through breast milk is minimal and does not typically affect the infant's thyroid function.

Q: How quickly do the side effects of Methizol usually go away?

A: Common, minor side effects, such as a mild feeling of nausea, often subside within the first two weeks as the body adjusts to the medication. Other side effects may require further medical evaluation or dosage adjustment.

Q: Can I take Methizol with my daily vitamins?

A: Methizol may interfere with the action of Vitamin K, a risk that physicians often monitor. Additionally, large doses of Biotin (Vitamin B7) can alter the results of thyroid function blood tests, requiring caution around testing times.

Q: How long does Methizol stay in your system?

A: Methizol has an elimination half-life that typically ranges from 4 to 6 hours. The half-life describes the time required for half of the dose to be cleared from the body.

Q: What happens if I accidentally take too much Methizol?

A: Taking too much may cause thyroid hormone levels to drop excessively (hypothyroidism) or increase the risk of rare, serious complications. Accidental overdose necessitates immediate evaluation by a healthcare professional.

Q: What medical tests are required before starting Methizol?

A: Before starting therapy, baseline laboratory tests are typically requested to aid in monitoring for potential serious adverse effects. These include a complete blood count (CBC) and liver function tests (LFTs).

Q: Are there any known eye or vision issues linked to Methizol use?

A: The drug is associated with central nervous system effects such as dizziness and a spinning sensation (vertigo). Blurred vision is also noted as a potential symptom of hypoglycemia (low blood sugar), which can be an adverse effect.

Q: Are there common signs that Methizol is working?

A: Yes, common initial signs that the treatment is effective include feeling an improvement in hyperthyroid symptoms. For example, a reduced heart rate and less heat intolerance may become noticeable within 2 to 4 weeks of therapy.

Q: Can Methizol cause changes in mood or behavior?

A: Mood and behavior changes, such as depression, are documented signs of drug-induced hypothyroidism. This condition can result from treatment and may be addressed through appropriate dose adjustment.

Q: Does Methizol affect blood sugar levels?

A: Yes, official product information indicates that Methizol can cause low blood sugar (hypoglycemia), which is a serious adverse effect. If symptoms like dizziness or fast heartbeat occur, the condition should be promptly reported to a healthcare provider.

Q: Can I safely drive while taking Methizol?

A: Because the drug can cause side effects like drowsiness and dizziness, caution is advised when driving or operating machinery until the effects of the medication on individual alertness are known. This is a standard safety recommendation.

How should Methizol be stored and disposed of?

How to Store and Dispose of Methizol (Methimazole)

Methizol tablets must be stored at controlled room temperature, specifically within the range of 15 C to 30 C (59 F to 86 F).


Storage Requirements

The medication must be kept in its original container and the container must remain tightly closed to protect the tablets from light and moisture. Storage must be in a dry place, and areas subject to excessive heat should be avoided. A mandatory requirement is to keep this and all drugs out of the sight and reach of children.

Disposal Instructions

Unused or expired Methizol should be disposed of through a dedicated drug take-back program when available. It is advised not to flush the tablets down the toilet or pour them into a drain. Consult local regulations or a pharmacist for guidance on safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Methizol found in:

A-Z Index: